FOLH1 and neoplasm: PSMA-targeted RLT using [177Lu]Lu-PSMA-617 has been shown to be effective in various retrospective studies [12–15] as well as in phase II [16, 17] and phase III trials [18] with low side effects while reducing tumor burden.